scholarly journals Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration

2021 ◽  
Vol Volume 13 ◽  
pp. 359-376
Author(s):  
Marcello Giunta ◽  
Eino Solje ◽  
Fabrizio Gardoni ◽  
Barbara Borroni ◽  
Alberto Benussi
Keyword(s):  
Frontotemporal Lobar Degeneration ◽  
Disease Modifying ◽  
Disease Modifying Agents ◽  
Experimental Disease

scholarly journals P2-298: Assessing the economic value of potential disease-modifying agents in Alzheimer's disease using simulation

2013 ◽  
Vol 9 ◽  
pp. P467-P467
Author(s):  
Denis Getsios ◽  
Shien Guo ◽  
Nikhil Revankar ◽  
Linus Jonsson ◽  
Peter Neumann ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Economic Value ◽  
Disease Modifying ◽  
Disease Modifying Agents

FRI0108 Risk for herpes zoster after treatment with biologic and synthetic disease modifying agents for rheumatoid arthritis

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 346.2-346
Author(s):  
D.A. Pappas ◽  
M. Hooper ◽  
G. Reed ◽  
Y. Shan ◽  
D. Wenkert ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Herpes Zoster ◽  
Disease Modifying ◽  
Disease Modifying Agents

scholarly journals Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 77-81 ◽  
Author(s):  
Corey Cutler
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Aplastic Anemia ◽  
Cell Transplantation ◽  
Significant Risk ◽  
Unrelated Donor ◽  
Hematopoietic Stem ◽  
Matched Sibling ◽  
Disease Modifying ◽  
Disease Modifying Agents

Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) is a potentially curative procedure, but is associated with a significant risk of morbidity and mortality. With the recent approval of disease-modifying agents, the appropriate timing of allogeneic HSCT needs to be addressed. Similarly, the optimal use of these disease-modifying agents before HSCT needs to be determined. In severe aplastic anemia, HSCT is a proven cure, but HLA-matched sibling donors are found in fewer than 25% of newly diagnosed patients. The use of early unrelated donor HSCT is an evolving concept that will become more accepted as improvements in HSCT outcomes continue.

Sign in / Sign up

Export Citation Format

Share Document